The University of Southampton
University of Southampton Institutional Repository

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study
Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study
Objectives: To compare the safety, reactogenicity, and immunogenicity of an adjuvanted split virion H1N1 vaccine and a non-adjuvanted whole virion vaccine used in the pandemic immunisation programme in the United Kingdom.

Design: Open label, randomised, parallel group, phase II study.

Setting: Five UK centres (Oxford, Southampton, Bristol, Exeter, and London).

Participants: Children aged 6 months to less than 13 years for whom a parent or guardian had provided written informed consent and who were able to comply with study procedures were eligible. Those with laboratory confirmed pandemic H1N1 influenza or clinically diagnosed disease meriting antiviral treatment, allergy to egg or any other vaccine components, or coagulation defects, or who were severely immunocompromised or had recently received blood products were excluded. Children were grouped by age: 6 months-<3 years (younger group) and 3-<13 years (older group). Recruitment was by media advertising and direct mailing. Recruitment visits were attended by 949 participants, of whom 943 were enrolled and 937 included in the per protocol analysis.

Interventions: Participants were randomised 1:1 to receive AS03B (tocopherol based oil in water emulsion) adjuvanted split virion vaccine derived from egg culture or non-adjuvanted whole virion vaccine derived from cell culture. Both were given as two doses 21 days apart. Reactogenicity data were collected for one week after immunisation by diary card. Serum samples were collected at baseline and after the second dose.

Main outcome measures: Primary reactogenicity end points were frequency and severity of fever, tenderness, swelling, and erythema after vaccination. Immunogenicity was measured by microneutralisation and haemagglutination inhibition assays. The primary immunogenicity objective was a comparison between vaccines of the percentage of participants showing seroconversion by the microneutralisation assay (fourfold rise to a titre of ?1:40 from before vaccination to three weeks after the second dose).

Results: Seroconversion rates were higher after the adjuvanted split virion vaccine than after the whole virion vaccine, most notably in the youngest children (163 of 166 participants with paired serum samples (98.2%, 95% confidence interval 94.8% to 99.6%) v 157 of 196 (80.1%, 73.8% to 85.5%), P<0.001) in children under 3 years and 226 of 228 (99.1%, 96.9% to 99.9%) v 95.9%, 92.4% to 98.1%, P=0.03) in those over 3 years). The adjuvanted split virion vaccine was more reactogenic than the whole virion vaccine, with more frequent systemic reactions and severe local reactions in children aged over 5 years after dose one (13 (7.2%, 3.9% to 12%) v 2 (1.1%, 0.1% to 3.9%), P<0.001) and dose two (15 (8.5%, 4.8% to 13.7%) v 2 (1.1%, 0.1% to 4.1%), P<0.002) and after dose two in those under 5 years (15 (5.9%, 3.3% to 9.6%) v 0 (0.0%, 0% to 1.4%), P<0.001). Dose two of the adjuvanted split virion vaccine was more reactogenic than dose one, especially for fever ?38ºC in those aged under 5 (24 (8.9%, 5.8% to 12.9%) v 57 (22.4%, 17.5% to 28.1%), P<0.001).

Conclusions: In this first direct comparison of an AS03B adjuvanted split virion versus whole virion non-adjuvanted H1N1 vaccine, the adjuvanted vaccine, while more reactogenic, was more immunogenic and, importantly, achieved high seroconversion rates in children aged less than 3 years. This indicates the potential for improved immunogenicity of influenza vaccines in this age group.

0959-8138
c2649
Waddington, Claire S.
160855ca-52a4-46a4-8f8b-c5fa07541d74
Walker, W.T.
b9981f69-8c4e-441d-93d7-d45e65341576
Oeser, C.
d43e7ab3-d8e8-44e4-b97f-5b834261bf80
Reiner, A.
3070c51c-7052-4e26-bb9b-3f0696777f35
John, T.
b3cb91b9-e90c-496b-bcd2-dd064b39c1f9
Wilkins, S.
670a1877-0266-45a3-abeb-83167a7bcdf7
Casey, M.
c4b63f72-5c46-422f-964a-1b0440df8caa
Eccleston, P.E.
264e08d9-7b69-4951-b578-bceefa804de1
Allen, R.J.
9ab9f03b-99e4-4667-8420-79b830f5b26a
Okike, I.
6930e709-add2-4f37-b921-75abab7d888e
Ladhani, S.
fb4dfe41-84b7-4133-a3d3-9e63171a6a4a
Sheasby, E.
e072d3b6-11b1-4d95-bc48-c889474911ad
Hoschler, K.
ee23d12e-ae8b-4376-87fd-9d1c4e850f45
Andrews, N.
9ab2a801-61e1-464c-b7d5-bec89042a873
Waight, P.
9c244d2d-c6a3-4d6f-9da4-7be6e8132a8f
Collinson, A.C.
4be2e3c6-c46c-44a0-bd97-79b89d2b60c3
Heath, P.T.
2e7a71a5-cc4a-4088-9295-cdc179a4e0ac
Finn, A.
51e100d7-bd49-442f-b50d-240841fa25f0
Faust, S.N.
f97df780-9f9b-418e-b349-7adf63e150c1
Snape, M.D.
2accdbd8-25fd-4c82-be53-8f7d607641d2
Miller, E.
4ed01267-aa3e-42a6-9331-00016aacc49f
Pollard, A.J.
53d9e953-ea8d-4d2c-b47d-82cf419615f8
Waddington, Claire S.
160855ca-52a4-46a4-8f8b-c5fa07541d74
Walker, W.T.
b9981f69-8c4e-441d-93d7-d45e65341576
Oeser, C.
d43e7ab3-d8e8-44e4-b97f-5b834261bf80
Reiner, A.
3070c51c-7052-4e26-bb9b-3f0696777f35
John, T.
b3cb91b9-e90c-496b-bcd2-dd064b39c1f9
Wilkins, S.
670a1877-0266-45a3-abeb-83167a7bcdf7
Casey, M.
c4b63f72-5c46-422f-964a-1b0440df8caa
Eccleston, P.E.
264e08d9-7b69-4951-b578-bceefa804de1
Allen, R.J.
9ab9f03b-99e4-4667-8420-79b830f5b26a
Okike, I.
6930e709-add2-4f37-b921-75abab7d888e
Ladhani, S.
fb4dfe41-84b7-4133-a3d3-9e63171a6a4a
Sheasby, E.
e072d3b6-11b1-4d95-bc48-c889474911ad
Hoschler, K.
ee23d12e-ae8b-4376-87fd-9d1c4e850f45
Andrews, N.
9ab2a801-61e1-464c-b7d5-bec89042a873
Waight, P.
9c244d2d-c6a3-4d6f-9da4-7be6e8132a8f
Collinson, A.C.
4be2e3c6-c46c-44a0-bd97-79b89d2b60c3
Heath, P.T.
2e7a71a5-cc4a-4088-9295-cdc179a4e0ac
Finn, A.
51e100d7-bd49-442f-b50d-240841fa25f0
Faust, S.N.
f97df780-9f9b-418e-b349-7adf63e150c1
Snape, M.D.
2accdbd8-25fd-4c82-be53-8f7d607641d2
Miller, E.
4ed01267-aa3e-42a6-9331-00016aacc49f
Pollard, A.J.
53d9e953-ea8d-4d2c-b47d-82cf419615f8

Waddington, Claire S., Walker, W.T., Oeser, C., Reiner, A., John, T., Wilkins, S., Casey, M., Eccleston, P.E., Allen, R.J., Okike, I., Ladhani, S., Sheasby, E., Hoschler, K., Andrews, N., Waight, P., Collinson, A.C., Heath, P.T., Finn, A., Faust, S.N., Snape, M.D., Miller, E. and Pollard, A.J. (2010) Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ, 340, c2649. (doi:10.1136/bmj.c2649). (PMID:9258541)

Record type: Article

Abstract

Objectives: To compare the safety, reactogenicity, and immunogenicity of an adjuvanted split virion H1N1 vaccine and a non-adjuvanted whole virion vaccine used in the pandemic immunisation programme in the United Kingdom.

Design: Open label, randomised, parallel group, phase II study.

Setting: Five UK centres (Oxford, Southampton, Bristol, Exeter, and London).

Participants: Children aged 6 months to less than 13 years for whom a parent or guardian had provided written informed consent and who were able to comply with study procedures were eligible. Those with laboratory confirmed pandemic H1N1 influenza or clinically diagnosed disease meriting antiviral treatment, allergy to egg or any other vaccine components, or coagulation defects, or who were severely immunocompromised or had recently received blood products were excluded. Children were grouped by age: 6 months-<3 years (younger group) and 3-<13 years (older group). Recruitment was by media advertising and direct mailing. Recruitment visits were attended by 949 participants, of whom 943 were enrolled and 937 included in the per protocol analysis.

Interventions: Participants were randomised 1:1 to receive AS03B (tocopherol based oil in water emulsion) adjuvanted split virion vaccine derived from egg culture or non-adjuvanted whole virion vaccine derived from cell culture. Both were given as two doses 21 days apart. Reactogenicity data were collected for one week after immunisation by diary card. Serum samples were collected at baseline and after the second dose.

Main outcome measures: Primary reactogenicity end points were frequency and severity of fever, tenderness, swelling, and erythema after vaccination. Immunogenicity was measured by microneutralisation and haemagglutination inhibition assays. The primary immunogenicity objective was a comparison between vaccines of the percentage of participants showing seroconversion by the microneutralisation assay (fourfold rise to a titre of ?1:40 from before vaccination to three weeks after the second dose).

Results: Seroconversion rates were higher after the adjuvanted split virion vaccine than after the whole virion vaccine, most notably in the youngest children (163 of 166 participants with paired serum samples (98.2%, 95% confidence interval 94.8% to 99.6%) v 157 of 196 (80.1%, 73.8% to 85.5%), P<0.001) in children under 3 years and 226 of 228 (99.1%, 96.9% to 99.9%) v 95.9%, 92.4% to 98.1%, P=0.03) in those over 3 years). The adjuvanted split virion vaccine was more reactogenic than the whole virion vaccine, with more frequent systemic reactions and severe local reactions in children aged over 5 years after dose one (13 (7.2%, 3.9% to 12%) v 2 (1.1%, 0.1% to 3.9%), P<0.001) and dose two (15 (8.5%, 4.8% to 13.7%) v 2 (1.1%, 0.1% to 4.1%), P<0.002) and after dose two in those under 5 years (15 (5.9%, 3.3% to 9.6%) v 0 (0.0%, 0% to 1.4%), P<0.001). Dose two of the adjuvanted split virion vaccine was more reactogenic than dose one, especially for fever ?38ºC in those aged under 5 (24 (8.9%, 5.8% to 12.9%) v 57 (22.4%, 17.5% to 28.1%), P<0.001).

Conclusions: In this first direct comparison of an AS03B adjuvanted split virion versus whole virion non-adjuvanted H1N1 vaccine, the adjuvanted vaccine, while more reactogenic, was more immunogenic and, importantly, achieved high seroconversion rates in children aged less than 3 years. This indicates the potential for improved immunogenicity of influenza vaccines in this age group.

This record has no associated files available for download.

More information

Published date: 2010
Organisations: Infection Inflammation & Immunity

Identifiers

Local EPrints ID: 175591
URI: http://eprints.soton.ac.uk/id/eprint/175591
ISSN: 0959-8138
PURE UUID: ccf90378-840e-4d1c-a45c-75f76b81da56
ORCID for S.N. Faust: ORCID iD orcid.org/0000-0003-3410-7642

Catalogue record

Date deposited: 24 Feb 2011 15:04
Last modified: 14 Mar 2024 02:51

Export record

Altmetrics

Contributors

Author: Claire S. Waddington
Author: W.T. Walker
Author: C. Oeser
Author: A. Reiner
Author: T. John
Author: S. Wilkins
Author: M. Casey
Author: P.E. Eccleston
Author: R.J. Allen
Author: I. Okike
Author: S. Ladhani
Author: E. Sheasby
Author: K. Hoschler
Author: N. Andrews
Author: P. Waight
Author: A.C. Collinson
Author: P.T. Heath
Author: A. Finn
Author: S.N. Faust ORCID iD
Author: M.D. Snape
Author: E. Miller
Author: A.J. Pollard

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×